郭军-北京大学肿瘤医院北京大学临床肿瘤学院、北京市肿瘤防治研究所

临床科室

医技科室

基础科室

行政处室

黑色素瘤与肉瘤内科 - 郭军

郭军简介

预约主任医师

主任医师，博士生导师，教授中国临床肿瘤学会(CSCO)副理事长兼秘书长CSCO黑色素瘤专家委员会主任委员CSCO肾癌专家委员会副主任委员CSCO免疫治疗专委会副主任委员CSCO尿路上皮癌专委会副主任委员CSCO前列腺癌专委会副主任委员Melanoma World Society (MWS) 副主席长期从事黑色素瘤、肾癌、膀胱癌、前列腺癌等皮肤、泌尿生殖肿瘤的临床和转化医学研究，对于个体化靶向治疗和生物免疫靶向治疗方面积累了丰富的临床经验。重要成果发表于J ClinOncol，Blood，Annals of Oncol, Nat Commun, ClinCan Res等重要SCI期刊，累计影响因子500余分，累计引用次数超过2000次。其中4篇文章被引入美国NCCN黑色素瘤、肾癌和头颈部肿瘤诊治指南(全国个人排名并列4)，多次入选ASCO年会口头报告。曾获北京市科技进步奖二等奖，中国抗癌协会科技奖二等奖，中华医学会科技奖…

主任医师，博士生导师，教授

中国临床肿瘤学会(CSCO)副理事长兼秘书长

CSCO黑色素瘤专家委员会主任委员

CSCO肾癌专家委员会副主任委员

CSCO免疫治疗专委会副主任委员

CSCO尿路上皮癌专委会副主任委员

CSCO前列腺癌专委会副主任委员

Melanoma World Society (MWS) 副主席

长期从事黑色素瘤、肾癌、膀胱癌、前列腺癌等皮肤、泌尿生殖肿瘤的临床和转化医学研究，对于个体化靶向治疗和生物免疫靶向治疗方面积累了丰富的临床经验。重要成果发表于J ClinOncol，Blood，Annals of Oncol, Nat Commun, ClinCan Res等重要SCI期刊，累计影响因子500余分，累计引用次数超过2000次。其中4篇文章被引入美国NCCN黑色素瘤、肾癌和头颈部肿瘤诊治指南(全国个人排名并列4)，多次入选ASCO年会口头报告。曾获北京市科技进步奖二等奖，中国抗癌协会科技奖二等奖，中华医学会科技奖三等奖等。

发表论文

1. Si L, Zhang X, Xu Z, Jiang Q, Bu L, Wang X, Mao L, Zhang W, Richie N, Guo J. Vemurafenib in Chinese patients with BRAFV600 mutation-positive unresectable or metastatic melanoma: an open-label, multicenter phase I study. BMC Cancer. 2018 May 3;18(1):520. IF=3.288

2. Cui C, Zhou L, Lian B, Si L, Sheng X, Chi Z, Kong Y, Wang X, Tang B, Mao L, Li S, Dai J, Yan X, Bai X, Guo J. Safety and Efficacy of Apatinib Combined with Temozolomide in Advanced Melanoma Patients after Conventional Treatment Failure. Transl Oncol. 2018 Oct;11(5):1155-1159. IF=3.071

3. Guo J, Jin J, Oya M, Uemura H, Takahashi S, Tatsugami K, Rha SY, Lee JL, Chung J, Lim HY, Wu HC, Chang YH, Azad A, Davis ID, Carrasco-Alfonso MJ, Nanua B, Han J, Ahmad Q, Motzer R. Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial. J Hematol Oncol. 2018 May 22;11(1):69. IF=7.333

4. Yu J, Wu X, Yan J, Yu H, Xu L, Chi Z, Sheng X, Si L, Cui C, Dai J, Ma M, Xu T, Kong Y, Guo J. Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients. J Hematol Oncol. 2018 Jan 3;11(1):1. IF=7.333

5. Cui C, Lian B, Zhou L, Song X, Zhang X, Wu D, Chi Z, Si L, Sheng X, Kong Y, Tang B, Mao L, Wang X, Li S, Dai J, Yan X, Bai X, Balch CM, Guo J. Multifactorial Analysis of Prognostic Factors and Survival Rates Among 706 Mucosal Melanoma Patients. Ann Surg Oncol. 2018 Aug;25(8):2184-2192. IF=3.857

6. Li S, Sheng X, Si L, Cui C, Kong Y, Mao L, Lian B, Tang B, Yan X, Wang X, Chi Z, Guo J. Outcomes and Predictive Factors of Isolated Limb Infusion for Patients with In-transit Melanoma in China. Ann Surg Oncol. 2018 Apr;25(4):885-893. IF=3.857

7. Tang H, Kong Y, Si L, Cui C, Sheng X, Chi Z, Dai J, Yu S, Ma M, Wu X, Yu J, Xu T, Yu H, Yan J, Guo J. Clinical significance of BRAFV600E mutation in circulating tumor DNA in Chinese patients with melanoma. Oncol Lett. 2018 Feb;15(2):1839-1844. IF=1.664

8. Sheng X, Cao D, Yuan J, Zhou F, Wei Q, Xie X, Cui C, Chi Z, Si L, Li S, Mao L, Lian B, Tang B, Yan X, Wang X, Kong Y, Dai J, Bai X, Zhou L, Guo J. Sorafenib in combination with gemcitabine plus cisplatin chemotherapy in metastatic renal collecting duct carcinoma: A prospective, multicentre, single-arm, phase 2 study. Eur J Cancer. 2018 Sep;100:1-7. IF=7.191

9. Sheng X, Bi F, Ren X, Cheng Y, Wang J, Rosbrook B, Jiang M, Guo J. First-line axitinib versus sorafenib in Asian patients with metastatic renal cell carcinoma: exploratory subgroup analyses of Phase III data. Future Oncol. 2019 Jan;15(1):53-63. IF=2.279.

10. Sheng X, Yan X, Chi Z, Si L, Cui C, Tang B, Li S, Mao L, Lian B, Wang X, Bai X, Zhou L, Kong Y, Dai J, Wang K, Tang X, Zhou H, Wu H, Feng H, Yao S, Flaherty KT, Guo J. Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G4 Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial. J Clin Oncol. 2019 Nov 10;37(32):2987-2999.IF = 28.349。

11. Newell F, Kong Y, Wilmott JS, Johansson PA, Ferguson PM, Cui C, Li Z, Kazakoff SH, Burke H, Dodds TJ, Patch AM, Nones K, Tembe V, Shang P, van der Weyden L, Wong K, Holmes O, Lo S, Leonard C, Wood S, Xu Q, Rawson RV, Mukhopadhyay P, Dummer R, Levesque MP, Jönsson G, Wang X, Yeh I, Wu H, Joseph N, Bastian BC, Long GV, Spillane AJ, Shannon KF, Thompson JF, Saw RPM, Adams DJ, Si L, Pearson JV, Hayward NK, Waddell N, Mann GJ, Guo J, Scolyer RA. Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets. Nat Commun. 2019 Jul 18;10(1):3163.IF = 11.878。

12. Yu J, Yan J, Guo Q, Chi Z, Tang B, Zheng B, Yu J, Yin T, Cheng Z, Wu X, Yu H, Dai J, Sheng X, Si L, Cui C, Bai X, Mao L, Lian B, Wang X, Yan X, Li S, Zhou L, Flaherty KT, Guo J, Kong Y. Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma. Clin Cancer Res. 2019 Nov 1;25(21):6511-6523. IF = 8.911

13. Tang B, Yan X, Sheng X, Si L, Cui C, Kong Y, Mao L, Lian B, Bai X, Wang X, Li S, Zhou L, Yu J, Dai J, Wang K, Hu J, Dong L, Song H, Wu H, Feng H, Yao S, Chi Z, Guo J. Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients. J Hematol Oncol. 2019 Jan 14;12(1):7. IF =8.731

14. Yu S, Dai J, Ma M, Xu T, Kong Y, Cui C, Chi Z, Si L, Tang H, Yang L, Sheng X, Guo J. RBCK1 promotes p53 degradation via ubiquitination in renal cell carcinoma. Cell Death Dis. 2019 Mar 15;10(4):254. IF =5.959

15. Yu J, Wu X, Yan J, Yu J, Yin T, Dai J, Ma M, Xu T, Yu H, Xu L, Yang L, Cheng Z, Chi Z, Sheng X, Si L, Cui C, Guo J, Kong Y. Potential Mutations in Uveal Melanoma Identified Using Targeted Next-Generation Sequencing. J Cancer. 2019 Jan 1;10(2):488-493. IF = 3.182

16. Cui C, Yan X, Liu S, Deitz AC, Si L, Chi Z, et al.. Real-world clinical outcomes of anticancer treatments in patients with advanced melanoma in China: retrospective, observational study. International Journal of Surgery: Oncology. 2019;4(6):e76. IF =3.158

17. Si L, Zhang X, Shu Y, Pan H, Wu D, Liu J, Lou F, Mao L, Wang X, Wen X, Gu Y, Zhu L, Lan S, Cai X, Diede SJ, Zhou Y, Ge J, Li J, Wu H, Guo J. A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151). Transl Oncol. 2019 Jun;12(6):828-835. IF =3.138

18. Wang X, Kong Y, Chi Z, Sheng X, Cui C, Mao L, Lian B, Tang B, Yan X, Si L, Guo J. Primary malignant melanoma of the esophagus: A retrospective analysis of clinical features, management, and survival of 76 patients. Thorac Cancer. 2019 Apr;10(4):950-956. IF = 2.524

19. Yan J, Xu L, Yu J, Wu X, Dai J, Xu T, Yu H, Guo J, Kong Y. Prognostic role of NRAS isoforms in Chinese melanoma patients. Melanoma Res. 2019 Jun;29(3):263-269. IF = 2.381

20. Sheng X, Bi F, Ren X, Cheng Y, Wang J, Rosbrook B, Jiang M, Guo J. First-line axitinib versus sorafenib in Asian patients with metastatic renal cell carcinoma: exploratory subgroup analyses of Phase III data. Future Oncol. 2019 Jan;15(1):53-63. IF = 2.279

21. Yan X, Sheng X, Chi Z, Si L, Cui C, Kong Y, Tang B, Mao L, Wang X, Lian B, Li S, Bai X, Zhou L, Dai J, Yao H, Guo J. Randomized Phase II Study of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma. J Clin Oncol. 2021 Mar 10;39(8):881-889. IF = 44.544.

22. Tang B, Chi Z, Chen Y, Liu X, Wu D, Chen J, Song X, Wang W, Dong L, Song H, Wu H, Feng H, Yao S, Qin S, Zhang X, Guo J. Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial. Clin Cancer Res. 2020 Aug 15;26(16):4250-4259. doi: 10.1158/1078-0432.CCR-19-3922. IF=10.107.

23. Si L, Zhang X, Shin SJ, Fan Y, Lin CC, Kim TM, Dechaphunkul A, Maneechavakajorn J, Wong CS, Ilankumaran P, Lee DY, Gasal E, Li H, Guo J. Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma. Eur J Cancer. 2020 Aug;135:31-38. IF=7.275

24. Sheng X, Yan X, Chi Z, Cui C, Si L, Tang B, Li S, Mao L, Lian B, Wang X, Bai X, Zhou L, Kong Y, Dai J, Ding L, Mao L, Guo J. Phase 1 trial of vorolanib (CM082) in combination with everolimus in patients with advanced clear-cell renal cell carcinoma. EBioMedicine. 2020 May;55:102755. IF=5.736

25. Yu J, Yu J, Wu X, Guo Q, Yin T, Cheng Z, Dai J, Kong Y, Guo J. The TERT copy number gain is sensitive to telomerase inhibitors in human melanoma. Clin Sci (Lond). 2020 Jan 31;134(2):193-205. IF=5.223

26. Wang X, Ji Q, Yan X, Lian B, Si L, Chi Z, Sheng X, Kong Y, Mao L, Bai X, Tang B, Li S, Zhou L, Cui C, Guo J. The Impact of Liver Metastasis on Anti-PD-1 Monoclonal Antibody Monotherapy in Advanced Melanoma: Analysis of Five Clinical Studies. Front Oncol. 2020 Sep 29;10:546604. IF=4.848

27. Wang ZL, Mao LL, Zhou ZG, Si L, Zhu HT, Chen X, Zhou MJ, Sun YS, Guo J. Pilot Study of CT-Based Radiomics Model for Early Evaluation of Response to Immunotherapy in Patients With Metastatic Melanoma. Front Oncol. 2020 Aug 25;10:1524. IF=4.848

28. Dai J, Yang L, Xu T, Si L, Cui C, Sheng X, Chi Z, Mao L, Lian B, Tang B, Bai X, Zhou L, Li S, Wang X, Yan X, Kong Y, Guo J. A Functional Synonymous Variant in PDGFRA Is Associated with Better Survival in Acral Melanoma. J Cancer. 2020 Mar 4;11(10):2945-2956. IF=3.565

29. Wang X, Xu W, Chi Z, Si L, Sheng X, Kong Y, Zhou L, Mao L, Lian B, Tang B, Yan X, Bai X, Cui C, Guo J. Chemotherapy combined with antiangiogenic drugs as salvage therapy in advanced melanoma patients progressing on PD-1 immunotherapy. Transl Oncol. 2021 Jan;14(1):100949. IF=4.243

30. Tang B, Chi Z, Guo J. Toripalimab for the treatment of melanoma. Expert Opin Biol Ther. 2020 Aug;20(8):863-869. IF=3.224

31. Sheng X, Jin J, He Z, Huang Y, Zhou A, Wang J, Ren X, Ye D, Zhang X, Qin S, Zhou F, Wang B, Guo J. Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies. BMC Cancer. 2020 Mar 14;20(1):219. IF=3.15

32. Yu J, Xu L, Yan J, Yu J, Wu X, Dai J, Guo J, Kong Y. MUC4 isoforms expression profiling and prognosis value in Chinese melanoma patients. Clin Exp Med. 2020 May;20(2):299-311.IF=2.644

33. Bai X, Kim M, Kasumova G, Si L, Tang B, Cui C, Yang X, Wei X, Cohen J, Lawrence D, Freedman C, Fadden R, Rubin K, Sharova T, Frederick D, Flaherty K, Sullivan R, Guo J, Boland G. Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohort. J Immunother Cancer. 2021 Feb;9(2):e002092. (IF=13.751)

34. Sheng X, Yan X, Wang L, Shi Y, Yao X, Luo H, Shi B, Liu J, He Z, Yu G, Ying J, Han W, Hu C, Ling Y, Chi Z, Cui C, Si L, Fang J, Zhou A, Guo J. Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma. Clin Cancer Res. 2021 Jan 1;27(1):43-51.IF=10.107. (IF=12.531)

35. Sheng X, Chen H, Hu B, Yao X, Liu Z, Yao X, Guo H, Hu Y, Ji Z, Luo H, Shi B, Liu J, Wu J, Zhou F, He Z, Fan J, Wang W, Feng H, Yao S, Keegan P, Huang Y, Guo J. Safety, Efficacy, and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter Phase II Trial POLARIS-03. Clin Cancer Res. 2022 Feb 1;28(3):489-497. (IF=12.531)

36. Bai X, Hu J, Betof Warner A, Quach HT, Cann CG, Zhang MZ, Si L, Tang B, Cui C, Yang X, Wei X, Pallan L, Harvey C, Manos MP, Ouyang O, Kim MS, Kasumova G, Cohen JV, Lawrence DP, Freedman C, Fadden RM, Rubin KM, Sharova T, Frederick DT, Flaherty KT, Rahma OE, Long GV, Menzies AM, Guo J, Shoushtari AN, Johnson DB, Sullivan RJ, Boland GM. Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 Monotherapy. Clin Cancer Res. 2021 Nov 1;27(21):5993-6000. (IF=12.531)

37. Mao L, Dai J, Cao Y, Bai X, Sheng X, Chi Z, Cui C, Kong Y, Zhang Y, Wu L, Wang X, Tang B, Lian B, Yan X, Li S, Zhou L, Wei X, Li C, Qi Z, Si L, Guo J. Palbociclib in advanced acral melanoma with genetic aberrations in the cyclin-dependent kinase 4 pathway. Eur J Cancer. 2021 May;148:297-306. IF=9.162

38. Tang B, Mo J, Yan X, Duan R, Chi Z, Cui C, Si L, Kong Y, Mao L, Li S, Zhou L, Lian B, Wang X, Bai X, Xu H, Li C, Dai J, Guo J, Sheng X. Real-world efficacy and safety of axitinib in combination with anti-programmed cell death-1 antibody for advanced mucosal melanoma. Eur J Cancer. 2021 Oct;156:83-92. IF=9.162

39. Mao L, Qi Z, Zhang L, Guo J, Si L. Immunotherapy in Acral and Mucosal Melanoma: Current Status and Future Directions. Front Immunol. 2021 Jun 4;12:680407. IF=7.561

40. Zhou L, Wang X, Chi Z, Sheng X, Kong Y, Mao L, Lian B, Tang B, Yan X, Bai X, Li S, Guo J, Cui C, Si L. Association of NRAS Mutation With Clinical Outcomes of Anti-PD-1 Monotherapy in Advanced Melanoma: A Pooled Analysis of Four Asian Clinical Trials. Front Immunol. 2021 Jul 5;12:691032. IF=7.561

41. Cui C, Xu C, Yang W, Chi Z, Sheng X, Si L, Xie Y, Yu J, Wang S, Yu R, Guo J, Kong Y. Ratio of the interferon-γ signature to the immunosuppression signature predicts anti-PD-1 therapy response in melanoma. NPJ Genom Med. 2021 Feb 4;6(1):7. IF=8.617

42. Mao L, Ding Y, Bai X, Sheng X, Dai J, Chi Z, Cui C, Kong Y, Fan Y, Xu Y, Wang X, Tang B, Lian B, Yan X, Li S, Zhou L, Wei X, Li C, Guo J, Zhang X, Si L. Overall Survival of Patients With Unresectable or Metastatic BRAF V600-Mutant Acral/Cutaneous Melanoma Administered Dabrafenib Plus Trametinib: Long-Term Follow-Up of a Multicenter, Single-Arm Phase IIa Trial. Front Oncol. 2021 Aug 24;11:720044. IF=6.244

43. Bai X, Dai J, Li C, Cui C, Mao L, Wei X, Sheng X, Chi Z, Yan X, Tang B, Lian B, Wang X, Zhou L, Li S, Kong Y, Qi Z, Xu H, Duan R, Guo J, Si L. Risk Models for Advanced Melanoma Patients Under Anti-PD-1 Monotherapy-Ad hoc Analyses of Pooled Data From Two Clinical Trials. Front Oncol. 2021 May 20;11:639085. IF=6.244

44. Wang X, Ji Q, Yan X, Lian B, Si L, Chi Z, Sheng X, Kong Y, Mao L, Bai X, Tang B, Li S, Zhou L, Cui C, Guo J. The Impact of Liver Metastasis on Anti-PD-1 Monoclonal Antibody Monotherapy in Advanced Melanoma: Analysis of Five Clinical Studies. Front Oncol. 2020 Sep 29;10:546604. IF=6.244

联系电话：010-88121122、88196358 科室位置：北京海淀区阜成路52号（定慧寺）

出诊信息

知名专家主任医师副主任医师主治医师住院医师研究员副研究员助理研究员主任护师副主任护师主任药师副主任药师医师主管技师副主任技师 - 普通门诊专家门诊特需门诊专科门诊未开启预约时间未到可预约时间已过暂停假期约满停诊替诊被替诊换诊（*出诊信息仅供参考，以门诊公布为准）

科室	时段	星期一 11-18	星期二 11-19	星期三 11-20	星期四 11-21	星期五 11-22	星期六 11-23	星期日 11-24	星期一 11-25
肾癌黑色素瘤内科	上午				特需
肾癌黑色素瘤内科	下午

技术团队

郭军

回复问题 0 个
盛锡楠

回复问题 0 个
迟志宏

回复问题 0 个
斯璐

回复问题 0 个
王轩

回复问题 0 个
崔传亮

回复问题 0 个
毛丽丽

回复问题 0 个
连斌

回复问题 0 个
鄢谢桥

回复问题 0 个

擅长疾病

黑色素瘤: 源于皮肤,粘膜,眼和中枢神经系统色素沉着区域的黑素细胞的恶性肿瘤.每年美国有25000个恶性黑素瘤新增病例,死亡约6000人.发病率在急速上升.日光照射是危险因素,同样危险因素还包括家族史,发生恶性斑痣,较大的先天性黑素细胞痣和发育不良性痣综合征.黑人少见.多数恶性黑素瘤均起源于正常皮肤的黑素细胞,约40%~50%发生于色素痣.恶性黑素瘤在儿童中很少见,但可源于出生即有的非常巨大的色素痣…

所在科室

黑色素瘤与肉瘤内科

北京大学肿瘤医院黑色素瘤与肉瘤内科，始建于2005年，通过十余年的快速发展，科室具有强大的医疗科研团队，开设本院、南院共两个病区，以及临床转化实验室。年门诊量30000余人次，收治患者8000余人次。全科在编医生10名，研究人员2名, 合同医生1名，在编均为博士学位,其中主任医师4名，副主任医师4名，研究员1名，副研究员1名。学科带头人郭军主任，任Melanoma World Society (MWS) 副…